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Context: Patients with classic Congenital Adrenal Hyperplasia (CAH) are treated with lifelong
glucocorticoids (GCS). Cardiovascular (CV) and metabolic effects of such therapy in adolescents
have never been quantified.
Objective: To investigate left ventricular (LV) morphology, function and exercise performance in
adolescents with CAH.
Design and Setting: cross-sectional and controlled study conducted at a tertiary referral centre.
Patients:Twentypatientswith classicCAH(10 females) aged13.62.5yearsand20healthy controls
comparable for sex and pubertal status were enrolled in the study and compared to a group of
18 patients without CAH receiving a similar dose of GCS for Juvenile Idiopathic Arthritis (JIA).
Main Outcomes Measures: Echocardiographic assessment and symptom-limited exercise testing
were performed. Anthropometric, hormonal and biochemical parameters were also measured.
Results: Compared to healthy controls, patients with CAH exhibited an increased BMI (p0.001),
waist-to-height ratio (p0.001), percentage of body fat (p0.001) as well as higher insulin con-
centrations and HOMA index even after adjustment for BMI (p0.03 and p0.05, respectively).
Moreover, CAH patients exhibited an impaired exercise capacity as shown by reduced peak work-
load (9927 vs 12627 W, p0.01) and higher systolic blood pressure response at peak (15618
vs 13211 mmHg, p0.01; 4524 vs 2210 mmHg, p0.05) with respect to healthy controls.
CAH males displayed mild LV diastolic dysfunction as documented by significant prolongation of
both isovolumic relaxation time (IRT) (11818 vs 9811ms, p0.05) and mitral deceleration time
(MDT) (13825 vs 11115 ms, p0.01). No significant differences in CV function were found
between CAH and JIA patients.
Conclusion: Adolescents with CAH exhibit impaired exercise performance and enhanced systolic
blood pressure response during exercise. In our population, such abnormalities appear related to
GCS therapy rather than CAH per se. CAH males, but no females, present mild LV diastolic dys-
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function that correlates with testosterone concentrations suggesting a sex hormone related
difference.
Congenital Adrenal Hyperplasia (CAH) is a group ofgenetically transmitted enzymatic defects of gluco-
corticoid biosynthesis associatedwith insufficient cortisol
production and accumulation of intermediate precursors
(1). The 21-hydroxylase deficiency causes about 95% of
cases (1). CAH is commonly divided into the severe classic
and the milder nonclassic form. All CAH phenotypes are
associatedwith a salt-loss continuum.ClassicCAH is gen-
erally subdivided, depending on the extent of enzymatic
impairment, into the salt-wasting form (SW), presenting
withboth cortisol andaldosteronedeficiency, and the sim-
ple virilizing form (SV) characterized by an isolated cor-
tisol deficiency. Both conditions are associated with an-
drogen excess resulting in virilization of female external
genitalia.
In the classic form steroid treatment is necessary to pre-
vent adrenal crisis and suppress androgen excess. How-
ever, the therapeutic window is narrow, and supra-phys-
iological doses of glucocorticoids (GCS) are often used to
suppress androgen overproduction, especially in early in-
fancy (2). As a result, CAH patients may develop iatro-
genicCushing’s syndrome (1, 2), a condition that in adults
and children is associated with insulin-resistance, hyper-
tension and increased cardiovascular morbidity (3). On
the other hand, it is not even clear whether the negative
cardio-metabolic effects are likely to be related to gluco-
corticoids excess or, conversely, to reduced androgen pro-
duction, that could have a detrimental impact on the car-
diovascular (CV) system (4, 5).
Finally, low plasma epinephrine concentrations have
been found in CAH, probably due to the lack of endoge-
nous cortisol that normally promotes the development of
adrenal medulla (1). Epinephrine deprivation is likely to
affect exercise performance and may also have an addi-
tional detrimental effect on insulin-sensitivity (6).
In this intricate scenario, it is reasonable to expect a
high cardiovascular risk profile in CAH patients, as sug-
gested by the increasing number of studies showing a
higher risk of obesity, insulin-resistance and high blood
pressure (BP) in CAH children compared to the general
population (7). However, the impact of these risk factors
on heart structure and performance has never been sys-
tematically ascertained. Aim of the current study was to
assess earlyCV risk factors, left ventricular (LV)morphol-
ogy and function and exercise capacity in adolescentswith
CAH,matched heathy controls andGC-treated non-CAH
subjects with Juvenile Idiopathic Arthritis.
Patients and Methods
Patients
TwentyCAHpatients (10 females and10males), aged13.6
2.5years,were enrolled in the study.All patientswere affected by
classic CAH,with 15 having the SW (9males) and 5 the SV form
(1 male). Diagnosis was made on the basis of clinical evidence,
elevated basal serum 17-OH-Progesterone (17OHP), elevated
plasma renin in the SW forms, and confirmed by genetic tests in
all subjects. Mean age at diagnosis was 1.4 2.1 year. At study
entry the mean duration of hydrocortisone therapy was 12.2 
3.3 years with a mean dose of 15.0 3.9 mg/m2/die, given three
times daily.The50%of the total daily amountwas administered
in the morning, while the other two doses included 25% of the
daily dose each. The three doses of hydrocortisone were given at
07:00 a.m., 3:00 p.m., 11:00 p.m., respectively. Patients affected
by SW CAH also received 9-fludrocortisone at a mean dose of
54.8  22.6 mcg/m2/die. The adequacy of steroid therapy was
monitored periodically in accordance with current guidelines
(2). None of the patients used chronic treatments other than
steroids. Known comorbidities such as liver failure, kidney fail-
ure, heart disease andother concomitant chronicdiseases, aswell
as recurrent adrenal crisis in the 5 years before the study entry,
were considered as exclusion criteria.
Twenty healthy adolescents, statistically not different for sex,
pubertal status and physical activity were recruited as control
group from those attending the outpatient clinic for a general
pediatric control at “Federico II” University Hospital. Further-
more, in order to evaluate the influence of long-term glucocor-
ticoid treatment onCV function, independent of CAHper se, we
enrolled 18 (9 males) age- (13.4  3.4 years) and BMI- SDS
(0.94  0.88) matched patients affected by Juvenile Idiopathic
Arthritis (JIA) treated with similar doses of GCS (17.44  9.1
mg/m2/die) followed at Rheumatology facilities of the “Federico
II” University. Written informed consent was obtained from the
parents of all patients and controls. The study protocol con-
formed to the ethical guidelines of the Declaration of Helsinki
and it was approved by the Ethics Committee of the Federico II
University of Naples.
Study Protocol
At study entry both CAH patients and controls underwent a
complete physical examination including measures of height,
weight, waist and hip circumferences, heart rate. Body Mass
Index (BMI) was calculated as Kg/m2. BMI was normalized by
age and sex and expressed as Standard deviation score (SDS) in
accordance with Italian reference standards (8). Obesity was
defined by a BMI SDS  2. Waist circumference was measured
at the midpoint between the lower edge of the ribs in the mid-
axillary line and the top of the iliac crest by the same clinician.
Waist-to-height ratio (WtHR)was then calculated as an index of
visceral adiposity. Pubertal statuswasassessedaccording toTan-
ner staging (9, 10). Bone age was determined by using the TW2
method by two independent investigators (11). Height per bone
agewas than calculated and expressed as SDS in accordancewith
Italian reference standards (8). Total body fat percentage was
assessed by dual-energy X-ray absorptiometry (DEXA).
2 Congenital Adrenal Hyperplasia and Heart J Clin Endocrinol Metab
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 12 January 2015. at 02:42 For personal use only. No other uses without permission. . All rights reserved.
Systolic and diastolic blood pressures were measured in all
subjects in the right armwith a standard sphygmomanometer by
the same operator. Full blood count and coagulation status were
obtained from all subjects. Evaluation of lipid profile was per-
formed, measuring total and HDL cholesterol and triglycerides.
LDLcholesterolwas calculatedbyusing theFriedewald formula.
Fasting blood samples for measurement of insulin and glucose
levels were obtained. Insulin-resistance was estimated using the
HomeOstasiticModelAssessment (HOMA) method according
to the formula: IRinsulin (mU/ml) x glucose (mmol/l)/22.5
(12). Coagulation state was assessed by measuring prothrom-
bine time (PT), activate partial thromboplastine (aPTT), and
fibrinogen levels. The adequacy of hormonal therapy at the time
of the study was assessed by measuring ACTH, testosterone,
17-OHP, androstenedione (4-A), DHEA-S, plasma renin and
serum electrolytes. Inhibin B concentrations were assessed in
male subjects to assess Sertoli cell function. To evaluate any
influence of gender or enzymatic impairment degree on cardio-
vascular and metabolic features of CAH patients, males and fe-
males, as well as SW and SV patients, were separately assessed.
In order to assess the effect of treatment on metabolic and CV
parameterswe calculated themean hydrocortisone dosage in the
3 years before the study and we also designed an index of over-
treatment (number of episodes of serum 17-OHP  0.2 ng/ml
during the last three years of follow-up). Those subjectswho had
an index of overtreatment  3 were considered as overtreated.
Echocardiography
An ultrasound system equipped with a 2.5 MHz multifre-
quency transducer (Aplio, Toshiba, Japan) was used for com-
plete M-mode, two-dimensional, Doppler and Tissue Doppler
Imaging (TDI) echocardiographic analyses. M-mode and two-
dimensional recordings were made according to current guide-
lines (13).Measures of LV end-diastolic volume (EDV) and end-
systolic volume (ESV)weremeasured by themodified Simpson’s
rule (13). Accordingly ejection fraction (EF) was calculated as
follows: EF  (EDV-ESV)/ESV*100. LV mass was calculated
according with America Society of Echocardiography-reco-
manded formula : LV mass  0.8*{1.04[( LVIDd  PWTd 
SWTd)3-(LVIDd)3]}  0.6 g where PWTd and SWTd are pos-
terior wall thickness at end diastole and septal wall thickness at
ed, respectively (13). The following parameters of diastolic func-
tionweremeasuredas themeanof three to five consecutivebeats:
diastolic transmitral peak velocities, E/A ratio, Isovolumic Re-
laxation Time (IRT), mitral deceleration time and pulmonary
vein velocities. Quantitative diastolic data were derived from
TDI analysis. Height2,7 was used for indexing LV cavity size.
This method has showed to be more sensible in identifying over-
weight subjects with LV hypertrophy (14). Measurement of all
parameters was performed off-line by one experienced investi-
gator blind to the study protocol (M.A.).
Exercise Test
All subjects underwent an incremental symptom-limited ex-
ercise test on a bicycle ergometer following Bruce protocol
(Yorba Linda, CA). We used this test for the evaluation of ex-
ercise capacity and BP levels at peak workload with 3-minutes
step incrementsof25Watts.All patientsweremonitoredbyEKG
for all the exercise duration. The exercise was stopped at the
achievement of the target heart rate (defined as the 85% of 220
- chronological age in years) or when participant refused to con-
tinue the exercise test, despite verbal encouragement from the
research staff. Maximal heart rate, SBP and DBP during the first
minute of each step were recorded at the end of the test. All tests
were closely physician-monitored and performed in the morn-
ing, after an overnight fast. The morning doses of HC and fluo-
drocortisonewere administered at the endof the test.All patients
familiarized with the ergometer at least one week before the test,
in order to avoid psychological stress.
Statistics
Statistical analysis was performed using SPSS (Chicago, IL,
USA). Data are expressed as mean Standard Deviation (SD).
Variables were analyzed by Kolmogorov-Smirnov test and pos-
itively skewed variables were log-transformed for analysis. In-
dependent t test for unpaired samples, was used to compare
patients and controls. Since patients and controls were statisti-
cally not different for sex and pubertal status but not for BMI, an
additional evaluation between groups was performed, using a
linear regression model (ANCOVA) after adjustment for BMI.
Bivariate correlations were calculated between hormonal and
cardiovascular parameters. Significance was set at 5%.
Results
Table 1 describes the anthropometric, biochemical and
hormonal characteristics of patients and healthy controls:
males and females are reported separately.All subjects had
entered puberty before the study entry. Seven femaleswith
CAH experienced menarche at a mean age of 11.5 years
statistically not different with the control group. All pa-
tients who experienced menarche had regular menses.
Boneage in thepatients groupwasadvancedbyanaverage
of two years (range 0.5–2.7 yrs), compared to chronolog-
ical age. Compared to healthy controls, adolescents with
CAH exhibited increased visceral adiposity, as suggested
by higher values of BMI SDS (1.02 0.92 vs –0.24 1.5,
P .0028), waist circumference (83 13 vs 72 14 cm,
P  .01), hip circumference (86  9 vs 78  12 cm, P 
.05) andWtHR(0.550.08vs0.470.07cm,P .001),
regardless of the sex. Moreover, DEXA analysis revealed
higher values of total body fat (35  8 vs 26  8%, P 
.001) in patients with CAH, with similar values of lean
mass between the two groups (table 1).
Lipid profile, coagulation parameters, full blood count
and fasting glycaemia were similar between patients and
healthy controls.
Fasting insulin concentrations and HOMA index, al-
though within normal values, were significantly higher in
CAH patients, compared to healthy controls, even after
adjustment for BMI (P  .03 and P  .05, respectively),
thus suggesting a tendency toward reduced insulin
sensitivity.
As expected, serum 17-OHP concentrations were sig-
nificantly higher in CAH patients, compared to healthy
doi: 10.1210/jc.2014-1805 jcem.endojournals.org 3
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 12 January 2015. at 02:42 For personal use only. No other uses without permission. . All rights reserved.
controls. Despite the higher 17-OHP concentrations,
CAH males showed lower testosterone concentrations
when compared to male healthy controls (P .05) (table
1).Toassess Sertoli cell functionwenextmeasured inhibin
B serum concentrations inmale subjects.Wedidnot found
any difference between male CAH and healthy controls
(100.0  8.1 vs 96.3  5.0 pg/ml, respectively; p: 0.25-
data not shown in Table 1).
Table 2 shows CV parameters and exercise capacity in
bothCAHpatients andhealthy controls.Nodifferences in
resting systolic and diastolic BP as well as heart rate were
observed between patients and healthy controls. Echocar-
diographic data showed that cavity size was statistically
not different between groups, regardless of the indexing
method used (Body surface area or height2,7). CAHmales
displayed a significant prolongation of both isovolumic
relaxation time (IRT) and mitral deceleration time
(MDT), even after adjustment for BMI (P .001 for both
parameters), consistent with mild diastolic dysfunction.
Furthermore, when considering separately SW and SV
forms, they both showed the same pattern of CV impair-
ment (Table 3). No differences in diastolic function and
exercise capacity were observed between overtreated and
normo-/undertreated patients (Table 3).
Interestingly, a significant negative correlation was
found between serum testosterone concentrations and
both IRT (r –0.864,P .02) andMDT (r –0.764,P
.001), as well as between testosterone concentrations and
mean hydrocortisone dosage (r –0,7148, P  0,02).
Both male and female CAH shared a pattern of im-
paired exercise capacity as documented by the reduced
peak workload (figure 1). Moreover, CAH patients
showedan exaggerated SBPat peakof exertion, regardless
of the sex (Table 2).Differences in peakworkload and SBP
at peak of exertion remained all significant even after ad-
justment for BMI (adjusted P  .03 and 0.0001,
respectively).
Bivariate analysis showed a significant positive corre-
lation betweenHOMA index and both SBP (r 0.65,P
.001), and SBP (r  0.55 P  .05), thus suggesting a
pivotal role of insulin in BP control.
Patients with JIA, treated with doses of GCS similar to
those employed in CAH, shared a similar CV phenotype.
In fact, compared to healthy controls, patients with JAI
displayed a mild diastolic dysfunction as well as an im-
paired exercise capacity (Table 4).
Discussion
The results of the present study show that our small cohort
of adolescents with CAH exhibits mild LV diastolic dys-
Table 1. Anthropometric, biochemical and hormonal characteristics of study population.
ALL CASES MALE FEMALE
Controls CAH Controls CAH Controls CAH
(n  20) (n  20) (n  10) (n  10) (n  10) (n  10)
Age (years) 13.7  2.4 13.6  2.5 13.7  1.7 14.0  2.7 14.7  2 13.0  2.4
Height SDS 0.52  1.8 0.49  1.1 0.57  1.2 0.25  1.2 0.47  2.3 0.74  0.1
Height per bone age SDS 1.23  0.48 1.29  0.71 1.03  0.28 1.02  0.71 1.44  0.61 1.56  0.65
BMI SDS 0.24  1.5 1.02  0.92** 0.33  1 1.26  0.93* 0.8  1.7 0.78  0.91 *
Waist circumference (cm) 72  14 83  13** 70  14 88  14** 76  14 77  10
Hip circumference (cm) 78  12 86  9* 74  11 91  10** 86  11 83  6
Waist/Height ratio 0.47  0.07 0.55  0.08*** 0.48  0.08 0.53  0.08** 0.47  0.06 0.56  0.08*
Total Body fat (%) 26  8 35  8** 25  5.8 31  8* 27  9 38  6 *
Total Body lean mass (%) 61.3  21.8 62.3  7.8 61  21.9 65  9 61.6  21.8 59.6  5.38
White blood cell count (x103/L) 7.4  2.5 8.1  1.6 6.5  1.8 7.7  1.5 8.3  2.7 8.6  1.8
Red blood cell count (x106/L) 4.8  0.4 4.9  0.3 5.1  0.3 5.2  0.3 4.4  0.2 4.7  0.5
Hemoglobin (g/dL) 13.7  1.2 13.9  0.9 14.5  0.8 13.8  1.4 13.3  0.7 12.9  0.8
Hematocrit (%) 39.5  3.4 41.2  3.2 41.1  3.2 42.8  3.1 38.1  3.1 39.5  2.6
Total cholesterol (mg/dL) 152  27 155  25 152  28 154  30 150  28 157  21
LDL cholesterol (mg/dL) 82  24 87  22 87  24 89  25 71  20 85  19
HDL cholesterol (mg/dL) 61  14 56  12 59  18 53  11 63  13 60  14
Triglycerides (mg/dL) 53  30 55  20 50  24 60  20 59  40 50  21
Glycemia (mg/dL) 75  6 72  6 77  6 73  6 71  7 70  6
Insulinemia (IU/mL) 5.2  2.0 12.0  7.0**** 5.4  5.7 11.1  7.2* 4.8  3.6 12.6  8.3**
HOMA index 1.0  0,4 2.0  1.3** 1.0  1 2.0  1.4* 1.0  0.6 2.0  1.3*
PT (sec) 12.3  0.7 12  0.7 12.2  0.5 11.7  0.6 12.5  0.5 12.3  0.8
APTT (sec) 33.3  3.6 33.6  3.4 35.7  2.4 33.2  3.6 31.2  3.1 34.0  3.2
Fibrinogen (mg/dL) 301.9  70.7 291.4  60.1 310.4  97.5 306.6  50.4 294.3  37.8 276.2  67.6
ACTH (pg/ml) 29.1  11 26.3  23 27.2  10.1 32.2  27.4 31.2  12.5 20.3  16.9
17-OH Progesterone (ng/mL) 0.6  0.3 12  15** 0.92  0.12 16.3  20.5* 0.6  0.4 7.9  6.2**
DHEA-S (g/dL) 45.3  23.4 52.5  64.4 44.4  28.8 40.3  28.7 46.2  18.2 64.7  87.1
Androstenedione (ng/dL) - - 70.7  22.2 165  162 87.5  29.3 160  118
Testosterone (ng/dL) - - 446.3  257.5 226.7  168.5* 27.4  7.7 31.5  8.8
Plasma renin (pg/mL) - 26.3  22.6 - 28.8  27.7 - 23.8  17.2
Hydrocortisone dose (mg/m2/day) - 15.0  3.9 - 16.6  2.6 - 13.5  4.6
9-fludrocortisone dose (mcg/m2/day) - 54.8  22.6 - 60.9  26.5 - 46.9  14.7
Data expressed as meanSD; ns, not significant.
CAH: Congenital Adrenal Hyperplasia; BMI: Body Mass Index; HOMA: HomeOstasis Model Assessment.
*P  0.05 vs. controls; **P  0.01 vs. controls; ***P  0.001 vs. controls; ****P  0.0001 vs. controls
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function, impaired exercise performance and enhanced
systolic BP response during exercise, compared to
matched healthy controls. Furthermore, in our cohort
bothCAHmales and females exhibit a cluster ofmetabolic
alterations such as increased visceral adiposity and a ten-
dency toward impaired insulin sensitivity, that may place
them at an increased risk of CV diseases in adulthood, in
agreement with recent studies [5]. Finally, such CV ab-
normalities appear related to GCS therapy rather than
CAH per se.
To date, data on cardiovascular function in patients
withCAHare scanty, however, impaired cardiac function
has been reported in subject with hypercortisolism due to
endogenous and exogenous Cushing’s Syndrome (15), as
well as in several others chronic endocrinopathies
(16–20).
To our knowledge this is the first study evaluating car-
diac function and exercise capacity in adolescents with
CAH.
In a recent study,Ubertini et al (21) reported a normal
LV mass in 20 young CAH patients. The study, however,
did not provide data on LV cavity size, systolic and dia-
stolic function. Another limit of the studywas the absence
of a control group. Consistently with Ubertini (21) we
observed anormal LVmorphology;moreover, for the first
time, we documented the presence of a mild diastolic dys-
function, that was a distinctive feature of male CAH.
An abnormal relaxation pattern without elevated rest-
ing diastolic filling may be related to both impaired insu-
lin-sensitivity (22) and obesity (23) through different
mechanisms suchas impaired insulin-signaling, glyco- and
lipo-toxicity, increased cytokine activity and interstitial
deposition of triacylglicerol and AGEs (24). In our pa-
tients, insulin and HOMA values, despite higher than
healthy controls, were still within the normal range, thus
their role in influencing diastolic function is questionable.
Conversely, in our patients diastolic dysfunction was sig-
nificantly associated with testosterone concentrations.
Whether androgen deficiency plays a role in CV system
development and function remains unknown, although
recent studies onyoungadultswithKlinefelter’s syndrome
point towardapossible association (18). Inadults, chronic
exposure to reduced androgens carry detrimental effects
on metabolic profile and cardiovascular status (4, 5) and
large epidemiological studies showed that low serum tes-
tosterone is an excellent biomarkerof cardiovascularmor-
tality (25). In fact, testosterone concentrations may exert
a protective effect on the progression of atherosclerosis
through both direct and mediated mechanisms (4, 5).
Our findings suggest that exposure to suboptimal tes-
tosterone levels during pubertal development, may have
exerted detrimental effects on cardiovascular perfor-
mance of males affected by CAH. In our patients, testos-
terone concentrations were negatively associated with
Table 2. Cardiovascular status and exercise capacity in controls and Congenital Adrenal Hyperplasia (CAH) patients
ALL CASES MALE FEMALE
Controls CAH Controls CAH Controls CAH
(n  20) (n  20) (n  10) (n  10) (n  10) (n  10)
LV EDV index (ml/m2,7-height) 27  8 27  9 27  8 23  11 26  9 31  3
LV ESV index (ml/m2,7-height) 10  3 11  4 11  3 10  4 9  2 12  3
LA diameter (mm) 27.0  4.3 29.5  4.7 27.2  4.4 31.1  5.9 26.8  4.4 28.0  2.6
LA volume index ( ml/m2,7-height) 13.8  3.4 15.2  3.7 12.6  3.3 14.5  4.9 15.0  3.1 15.5  1.2
Relative Wall Thickness 0.37  0.04 0.36  0.04 0.36  0.05 0.37  0.04 0.38  0.03 0.35  0.03
LV-mass index (g/m2,7-height) 33  10 35  12 30  8 31  16 35  12 40  7
Ejection Fraction (%) 60  9 60  6 58  7 59  5 62  11 62  7
MDT (ms) 116  18 138  22*** 111  15 138  25** 122  20 137  20
IRT (ms) 101  13 116  15* 98  11 118  18** 104  14 115  10
E/A 2.3  0.4 2.3  0.7 2.3  0.3 2.4  0.7 2.3  0.4 2.3  0.8
E’/A’ 3.0  0.8 3.3  0.9 3.2  0.9 3.6  1.2 2.7  0.4 3.0  0.5
E/E’ 7.6  1,4 7.4  1.8 8.1  1.4 7.4  2.3 7.2  1.2 7.4  1.4
adur-A dur (ms) 14.6  0.2 14.8  0.4 14.2  0.7 14.7  0.5 14.9  0.8 15.0  0.3
PVa (m/sec) 0.25  0.03 0.25  0.01 0.25  0.02 0.25  0.02 0.24  0.03 0.25  0.04
Heart Rate (bpm) 92  14 95  19 96  18 107  15 87  11 84  14
Resting SBP (mmHg) 110  7 111  11 111  7 110  12 110  5 111  11
Resting DBP (mmHg) 67  11 72  7 68  11 75  6 66  10 69  7
Peak Workload (W) 126  26 99  27** 135  26 102  18** 117  28 87  24**
Peak Heart Rate (bpm) 198  10 197  9 196  13 198  12 200  3 196  12
Peak SBP (mmHg) 132  11 156  18** 133  10 152  17* 131  12 159  20**
Peak DBP (mmHg) 70  10 76  8 70  12 77  5 70  7 75  11
 SBP (mmHg) 22  10 45  24* 23  12 46  26* 22  12 47  24*
 DBP (mmHg) 3.0  9 3.7  10 1.5  11 2.0  7 4.5  7 5.5  13
Data expressed as mean  SD; ns, not significant.
CAH: Congenital Adrenal Hyperplasia; LV: Left Ventricular; EDV: End-diastolic volume; ESV: End-systolic volume; LA: Left Atrial; MDT: Mitral
Deceleration Time; IRT: Isovolumic Relaxation Time
SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure;
 SBP (mmHg): difference between Resting SBP and peak SBP;  DBP (mmHg): difference between Resting DBP and peak DBP.
*P  0.5 vs. controls; **P  0.01 vs. controls; ***P  0.001 vs. controls; ****P  0.0001
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mean hydrocortisone dosage in the 3 years before the
study, thus suggesting that high hydrocortisone dosage
during puberty, although still within the recommended
range, may suppress testosterone production, thus in-
creasing the risk of early CV abnormalities (26).
Bothmales and femalesCAHshared a commonpattern
of exercise impairment and exaggerated BP response to
exercise. Exercise capacity in CAH adolescents has been
investigated both in short-term high intensity (6) and in
long-termmoderate intensity exercise (37).Weise et al (6)
performed a maximal incremental exercise test to deter-
mine maximal aerobic capacity in nine CAH adolescents
while Green-Golan and coworkers (27) investigated the
cardiovascular response to prolonged moderate-intensity
exercise in six adolescents with classic CAH. In contrast
with our results, both studies did not find any difference in
exercise capacity between CAH patients and healthy con-
trols. The small sample size of these two studies as well as
differences in the study population, (both studies evalu-
Table 3. Subgroup Analysis of diastolic function and exercise capacity in 1) Salt-wasting (SW) form patients vs.
age-matched controls 2) Simply virilizing (SV) form patients vs. age-matched controls 3) Overtreated patients vs.
normo-/undertreated patients.
Age-matched
controls SW form
Age-matched
controls SV form
Overtreated
CAH Normo-/Under-treated
(n  15) (n  15) (n  5) (n  5) (n  6) (n  14)
MDT
(ms)
111.8  16.9 137.6  23.8** 126.9  18.2 138.6  18.4 146.3  26.0 134.2  20.2
IRT
(ms)
100.9  13.1 114.6  13.4** 101.4  14.2 121.8  18.4* 120.0  19.7 114.9  12.4
E/A 2.3  0.4 2.3  0.8 2.2  0.9 2.3  0.2 2.7  0.9 2.1  0.4
E’/
A’
3.0  0.8 3.3  1.0 2.8  0.7 3.2  0.5 3.7  1.4 3.2  0.7
E/
E’
7.8  1.5 7.3  2.1 7.3  0.95 7.8  0.8 6.6  1.8 7.5  1.8
Peak
Workload
(W)
126.0  27.5 95.0  25.5*** 125.0  25.0 95.0  20.9* 87.5  20.9 98.2  22.9
Peak
Heart
Rate
(bpm)
196.7  10.7 197.1  12.8 202.4  6.2 195.4  9.4 203.2  8.9 193.9  12.2
Peak
SBP
(mmHg)
133.0  11.0 159.7  19.9****131.0  12.5 143.0  4.4* 156.6  23.2 155.0  17.4
Peak
DBP
(mmHg)
70.3  10.6 75.0  7.8 68.0  7.5 78.0  10.9 73.3  8.2 76.8  8.7

SBP
(mmHg)
24.4  11.6 43.3  27.0*** 10.0  12.5 30.0  3.5* 45.0  32.2 44.3  22.3

DBP
(mmHg)
3.3  9.75 3.6  9.1 2.0  5.7 4.0  3.9 6.6  12.1 2.5  12.5
Patients were considered “overtreated” if they had 3 episodes of serum 17-OHP 0.2 ng/ml during the last three years of follow-up.
*P  0.5 vs. controls; **P  0.01 vs. controls; ***P  0.001 vs. controls; ****P  0.0001
SW: Salt-wasting form; SV: Simply-virilizing form; MDT: Mitral Deceleration Time; IRT: Isovolumic Relaxation Time
SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure;
 SBP (mmHg): difference between Resting SBP and peak SBP;  DBP (mmHg): difference between Resting DBP and peak DBP.
Figure 1.
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ated only nonobese CAH subjects), may account for the
different results in exercise performance. In our study,
however, differences in peakworkload and SBP at peak of
exertion remained all significantly higher than healthy
controls even after adjustment for BMI. Moreover, a pos-
itive correlation was found between both peak SBP and
SBP and HOMA index. The relationship between insu-
lin-resistance and hypertension is well-known (1, 28),
however, despite higher insulin concentrations and
HOMAindex thanhealthy controls, our patientswere not
overtly insulin-resistant. Therefore, the hypothesis can be
put forward that other factors, such as the detrimental
effect of GCS on muscle performance (29) and the im-
paired release of epinephrine from the adrenomedullary of
CAH patients secondary to an altered medulla organo-
genesis (1) may played a key role in determining such
alterations.
Bloodpressure control inCAHhasbeen investigatedby
several independent groups, with some studies reporting
normal resting (21, 30, 31) and 24h BP profile (32) and
others reporting either diurnal (33) or both diurnal and
nocturnal SBP significantly elevated (34) and positively
related to increasedBMI. In the studybyUbertini et al (21)
systolic BP in response to exercise were substantially nor-
mal in CAH patients with good hormonal balance (35).
However, the wide age span (5.1–17.49 years), and the
lack of a control group might be responsible for the dif-
ferent results. In agreement with Ubertini et al (21), we
found normal resting BP with a slight trend in higher DBP
in CAH group (P  .09).
Overall these findings suggest that resting BP may be
unaffected by CAH,while BP control during normal daily
activities, as well as in response to exercise, may be im-
paired in CAH as a result of the metabolic disarray.
A similar pattern of cardiac abnormalities as well as of
impaired exercise capacity was observed in the group of
patients affected by JAI treatedwith similar doses of GCS,
thus suggesting that CV impairment was not related to
CAH per se but to a detrimental role of long-term GCS
treatment.
Despite GCS administration has dramatically changed
live expectancy of CAH patients, supra-physiological
doses ofGCSareoftennecessary to address several clinical
problems (32). First, intrauterine glucocorticoid defi-
ciency can lead to a condition of impaired postnatal pitu-
itary sensitivity to feedback inhibition (36). Second, ex-
ogenous administration of GCS and mineralocorticoids
cannot replicate the close temporal pattern of physiolog-
ical cortisol and aldosterone pulses (7) so that physicians
are tempted to overtreat in order to avoid crisis.
High CGS doses may, in turn, suppress testosterone
production, as observed in our male with CAH, thus in-
Table 4. Cardiovascular status and exercise capacity in Juvenile Idiopathic Arthritis (JIA) patients
JIA
Patients
p value vs.
Controls p value vs. CAH
(n  18)
Age (years) 13.4  3.4 ns ns
BMI (kg/m2) 0.94  0.88 0.01 ns
Hydrocortisone dose (mg/m2/day) 17.44  9.1 - ns
LV EDV index (ml/m2,7-height) 31  5 ns ns
LV ESV index (ml/m2,7-height) 11  3 ns ns
LA diameter (mm) 29.5  4.9 ns ns
LA volume index ( ml/m2,7-height) 16.1  5.6 ns ns
Relative Wall Thickness 0.37  0.03 ns ns
LV-mass index (g/m2,7-height) 33  8 ns ns
Ejection Fraction (%) 62  5 ns ns
MDT (ms) 155  33 0.001 ns
IRT (ms) 117  23 0.01 ns
E/A 2.1  0.5 ns ns
E’/A’ 3.3  0.9 ns ns
E/E’ 7.7  2.5 ns ns
adur-A dur (ms) 14.4  0.4 ns ns
PVa (m/sec) 0.24  0.02 ns ns
Heart Rate (bpm) 94  16 ns ns
Resting SBP (mmHg) 108  14 ns ns
Resting DBP (mmHg) 69  8 ns ns
Peak Workload (W) 86  21 0.0001 ns
Peak Heart Rate (bpm) 197  7 ns ns
Peak SBP (mmHg) 154  16 0.0001 ns
Peak DBP (mmHg) 72  11 ns ns
 SBP (mmHg) 47  19 0.0001 ns
 DBP (mmHg) 2.7  12.0 ns ns
ns: non significant
JIA: Juvenile Idiopathic Arthritis; CAH: Congenital Adrenal Hyperplasia;MDT: Mitral Deceleration Time; IRT: Isovolumic Relaxation Time
SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure;
 SBP (mmHg): difference between Resting SBP and peak SBP;  DBP (mmHg): difference between Resting DBP and peak DBP
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creasing the risk of early CV abnormalities. Although the
aim of our study was not to provide any pathophysiolog-
ical links between GCS replacement and CAH, our data
suggest that CV abnormalities found in our study popu-
lation are likely related to GCS administration. Indeed, a
cohort of patients affected by JIA that were statistically
comparable to our CAH sample for age, BMI and GCS
dose, showed a similar pattern of CV abnormalities.
Moreover, even though the evaluation of the effects of
glucocorticoid therapy on CV status in the general prepu-
bertal population was not the main aim of our study, this
may represent a stimulus for future studies aimed at eval-
uating dose dependency, permanence of glucocorticoid
therapy in children.Recent studies onAddisondisease, the
most common acquired adrenal failure (37), revealed an
increased risk for cardiovascular death in patients of both
sexes likely related to high doses of GCS (38). Because
CAH patients are treated with even higher doses of GCS
than Addison’s patients, further longitudinal investiga-
tions from large international registries are necessary to
assess such a risk in CAH patients.
In conclusion our data suggest, for the first time, that
adolescents with CAH are at risk for subclinical cardio-
vascular abnormalities, such as diastolic dysfunction (39)
and enhanced exercise BP (40). A careful anthropometric
andmetabolicmonitoring, especially during puberty,may
be helpful in this clinical setting in order to implement
early life-style modification and to prevent the develop-
ment of visceral adiposity and insulin resistance related to
glucocorticoid therapy, which in turn may led to CV ab-
normalities. Moreover, CAH patients may exhibit in-
creased abdominal adiposity, a trend toward insulin-re-
sistance, and a low testosterone exposure in males, as a
possible effect of overtreatment, that may play an addi-
tional detrimental role on CV performance.
Further studies on larger cohorts are necessary to better
clarify the mechanisms leading to metabolic and cardio-
vascular abnormalities, in the meanwhile, additional ef-
fort to avoid the complete suppression of androgens con-
centrations, especially in males, should represent a
therapeutic goal for improving management of peri-pu-
bertal patients with CAH.
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